tbuckley/cabot-search huggingface dataset:
OP0140 Ctla4Ig substantially augments the benefits of cyclophosphamide for lupus nephritis
Authors: P Kaufman, DI Daikh
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> We have recently shown that combining CTLA4Ig with cyclophosphamide (CTX) results in a marked reversal of active lupus nephritis in NZB/NZW mice. To determine whether similar benefit might be obtained with less CTX, we have compared the effect of a single dose of CTX combined with CTLA4Ig with that of continuous CTX and CTLA4Ig administration. Female mice were treated with either continuous CTX (50 mg/kg every 10 days × 7 weeks), continuous CTLA4Ig (50 mg ip 3×/week × 8 weeks), a single ip injection of CTX (50 mg/kg) plus brief CTLA4Ig (50 mg/kg ip 3×/week x 2 weeks), a single dose of cyclophosphamide (50 mg/kg ip) plus continuous CTLA4Ig, continuous CTX + CTLA4Ig, or saline. After 8 weeks, none of the treated mice had died, while 36% of the saline group had significant proteinuria and 18% had died. Mice that had received either continuous CTX, or a combination of prolonged CTLA4Ig with either prolonged or brief CTX had preserved kidney function (&gt;50% vs &lt;10%). However, survival in the CTX alone group was reduced compared with either the continuous CTX+CTLA4Ig or the single dose CTX+continuous CTLA4Ig groups (73% vs 100%). In a subsequent experiment, NZB/NZW mice with either mild of advanced renal disease were treated with low dose CTX (5 mg/kg) or high dose CTX (50 mg/kg) in combination with CTLA4Ig. Although mice with advanced renal disease that received either low dose or high dose CTX plus CTLA4Ig had a reduction in proteinuria compared to controls, the improvement was significantly greater among mice receiving the higher dose of CTX. However, among mice with mild disease, the delay in progression of proteinuria was equivalent in mice that received either low dose or high dose CTX in combination with CTLA4Ig. These results indicate that the benefits of CTX in murine lupus nephritis are amplified or sustained by CTLA4Ig, and that the clinical benefits of combining these agents might be realised while at the same time reducing exposure to CTX. <h3>Reference</h3> Supported by the Veterans Administration and NIAID
385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Authors: F. Barlesi, J. Wolf, M-J. Ahn, R.C. Doebele, L. Paz-Ares, C. Rolfo, S. Siena, T. Seto, Y. Ohe, S.H.I. Ou, M.G. Krebs, A. Kapre, E. Piault-Louis, S. McCallum, S. Osborne, A. Aziez, A. Drilon
Journal: Annals of Oncology (2020)
14290 Long-term results of dupilumab in the treatment of moderate to severe atopic dermatitis: The experience of five reference dermatology units in Spain
Authors: José Juan Pereyra-Rodriguez, Ricardo Ruiz Villaverde, J.J. Dominguez-Cruz, Sara Alcantara Luna, José C. Armario-Hita
Journal: Journal of the American Academy of Dermatology (2020)
15591 CD4+ small/medium T-cell lymphoproliferative disorder: A Mayo Enterprise experience
Authors: Jake Besch-Stokes, Collin M. Costello, Puneet Bhullar, Connor Maly, David Joseph DiCaudo, Nneka Comfere, William G. Rule, Fiona E. Craig, Allison Rosenthal, Mark R. Pittelkow, Aaron R. Mangold
Journal: Journal of the American Academy of Dermatology (2020)
15960 Safety of tildrakizumab in patients with preexisting metabolic syndrome: Long-term data from the post hoc analysis of two phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)
Authors: Mark G. Lebwohl, Nehal N. Mehta, Alice B. Gottlieb, Alan M. Mendelsohn, Jeff Parno, Stephen J. Rozzo, M. Alan Menter
Journal: Journal of the American Academy of Dermatology (2020)
Genetic profiling in esophageal cancer: Differential gene expression signatures in squamous cell carcinomas and adenocarcinomas and recurrent amplifications using array CGH
Authors: Anna Isinger, Ana Vasconcelos-Dias, Anna Karlsson, Jan Johansson, Mef Nilbert
Journal: Cancer Research (2006)

853  We aimed to develop a molecular classifier for esophageal cancer, which is the sixth most common cause of death from cancer worldwide. Early tumor detection through tailored surveillance programs and improved prognostics in patients with established tumors could improve survival in patients affected with these aggressive tumors. The tumors are subdivided into squamous cell carcinoma, which is the predominant form, and adenocarcinoma, which is linked to gastro-esophageal reflux through development of Barrett-type metaplasia. Cytogenetic studies have revealed multiple chromosomal aberrations in both tumor types. We applied expression microarray and array CGH to assess differences in genetic profiles in esophageal cancer with correlation to tumor location. cDNA extracted from 10 squamous cell carcinomas and 27 adenocarcinomas was applied to a 27K oligo microarray. Distinct expression profiles with multiple genes discriminating the squamous cell carcinomas from the adenocarcinomas were identified. Moreover, adenocarcinomas located in the ventricle could be distinguished from tumors in the distal esophagus. Array CGH (32K) were then used to further characterize genomic alterations in both groups. When array CGH was applied to 23 adenocarcinomas, several regions with high-level amplifications were identified, including 2q, 6p, 7q, 11q, 12p, 13q, 17q, 19q and 20q and losses were found to affect 3p, 4p, 9p, 16q, 19p and 20p. Array CGH of 30 squamous cell carcinomas showed gains that included 3q, 8q, 16, 17, 19 and 20 and losses of 3p, 4, 6q, 18q and 21q. Among the genes frequently amplified in esophageal carcinoma were EGFR, ERBB2, MYC, and various cyclins. In summary, distinct gene expression signatures are identified in squamous cell carcinomas and adenocarcinomas in the esophagus, whereas a weaker signal distinguishes adenocarcinomas in different locations. Recurrent amplifications and deletions are identified in both tumor types and may provide a basis for identification of novel markers for early tumor detection and improved prognostication.
Lung transplantation for patients with severe COVID-19
Authors: Ankit Bharat, Melissa Querrey, Nikolay S. Markov, Samuel Kim, Chitaru Kurihara, Rafael Garza-Castillon, Adwaiy Manerikar, Ali Shilatifard, Rade Tomic, Yuliya Politanska, Hiam Abdala-Valencia, Anjana V. Yeldandi, Jon W. Lomasney, Alexander V. Misharin, G. R. Scott Budinger
Journal: Science Translational Medicine (2020)

Some patients with severe COVID-19 develop end-stage pulmonary fibrosis for which lung transplantation may be the only treatment.
STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone): Is the Biggest Big Enough?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Juan Carlos Kaski, Gillian W. Cockerill
Journal: Journal of the American College of Cardiology (2009)
Abstract PO-42: TBL1XR1 mutations drive extranodal lymphomagenesis by inducing a protumorigenic memory B-cell fate
Authors: Leandro Venturutti, Matt Teater, Andrew Zhai, Amy Chadburn, Leena Babiker, Daleum Kim, Louis Staudt, Michael Green, Pedro Farinha, Andrew Weng, Christian Steidl, Ryan Morin, David Scott, Gil Privé, Ari Melnick
Journal: Blood Cancer Discovery (2020)

Abstract The most aggressive B-cell lymphomas frequently manifest extranodal distribution and carry somatic mutations in the poorly characterized gene TBL1XR1. Here, we show that TBL1XR1 mutations skew the humoral immune response towards generating abnormal immature memory B-cells (MB), while impairing plasma cell differentiation. At the molecular level, TBL1XR1 mutants co-opt SMRT/HDAC3 repressor complexes towards binding the MB cell transcription factor (TF) BACH2, at the expense of the germinal center (GC) TF BCL6, leading to pre-memory transcriptional reprogramming and cell-fate bias. Upon antigen recall, TBL1XR1 mutant MB cells fail to differentiate into plasma cells and instead preferentially reenter new GC reactions, providing evidence for a cyclic re-entry lymphomagenesis mechanism. Ultimately, TBL1XR1 alterations lead to a striking extranodal immunoblastic lymphoma phenotype that mimics the human disease. Both human and murine lymphomas feature expanded MB-like cell populations, consistent with a MB-cell origin and delineating an unforeseen pathway for malignant transformation of the immune system. Citation Format: Leandro Venturutti, Matt Teater, Andrew Zhai, Amy Chadburn, Leena Babiker, Daleum Kim, Louis Staudt, Michael Green, Pedro Farinha, Andrew Weng, Christian Steidl, Ryan Morin, David Scott, Gil Privé, Ari Melnick. TBL1XR1 mutations drive extranodal lymphomagenesis by inducing a protumorigenic memory B-cell fate [abstract]. In: Proceedings of the AACR Virtual Meeting: Advances in Malignant Lymphoma; 2020 Aug 17-19. Philadelphia (PA): AACR; Blood Cancer Discov 2020;1(3_Suppl):Abstract nr PO-42.
Omics and interspecies interaction
Authors: Bhumika Shokeen, Marcia Dalila Botelho Dinis, Farnoosh Haghighi, Nini Chaichanasakul Tran, Renate Lux
Journal: Periodontology 2000 (2020)

Abstract Interspecies interactions are key determinants in biofilm behavior, ecology, and architecture. The cellular responses of microorganisms to each other at transcriptional, proteomic, and metabolomic levels ultimately determine the characteristics of biofilm and the corresponding implications for health and disease. Advances in omics technologies have revolutionized our understanding of microbial community composition and their activities as a whole. Large‐scale analyses of the complex interaction between the many microbial species residing within a biofilm, however, are currently still hampered by technical and bioinformatics challenges. Thus, studies of interspecies interactions have largely focused on the transcriptional and proteomic changes that occur during the contact of a few prominent species, such as Porphyromonas gingivalis , Streptococcus mutans , Candida albicans , and a few others, with selected partner species. Expansion of available tools is necessary to grow the revealing, albeit limited, insight these studies have provided into a profound understanding of the nature of individual microbial responses to the presence of others. This will allow us to answer important questions including: Which intermicrobial interactions orchestrate the myriad of cooperative, synergistic, antagonistic, manipulative, and other types of relationships and activities in the complex biofilm environment, and what are the implications for oral health and disease?
The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing
Authors: Josu de la Fuente, Eliane Gluckman, Julie Makani, Paul Telfer, Lawrence Faulkner, Selim Corbacioglu, Persis Amrolia, Marc Ansari, Adriana Balduzzi, Arnaud Dalassier, Jean-Hugues Dalle, Cristina Hereda Diaz, Tobias Feuchtinger, Franco Locatelli, Giovanna Lucchini, Jaques-Emmanuel Galimard, Marta Gonzalez Vincent, Rupert Handgretinger, Katharina Kleinschmidt, Anita Lawitschka, Antonio Perez Martinez, Christina Peters, Vanderson Rocha, Annalisa Ruggeri, Petr Sedlacek, Peter Svec, Jacek Toporski, Akif Yesilipek
Journal: The Lancet Haematology (2020)
Enhanced epigenetic profiling of classical human monocytes reveals a specific signature of healthy aging in the DNA methylome
Authors: Irina Shchukina, Juhi Bagaitkar, Oleg Shpynov, Ekaterina Loginicheva, Sofia Porter, Denis A. Mogilenko, Erica Wolin, Patrick Collins, German Demidov, Mykyta Artomov, Konstantin Zaitsev, Sviatoslav Sidorov, Christina Camell, Monika Bambouskova, Laura Arthur, Amanda Swain, Alexandra Panteleeva, Aleksei Dievskii, Evgeny Kurbatsky, Petr Tsurinov, Roman Chernyatchik, Vishwa Deep Dixit, Marko Jovanovic, Sheila A. Stewart, Mark J. Daly, Sergey Dmitriev, Eugene M. Oltz, Maxim N. Artyomov
Journal: Nature Aging (2020)
185P Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Authors: L-Q. Wang, Y-K. Wu, Z. Xue, C-H. Zheng, P. Li, J-W. Xie, J-B. Wang, J-X. Lin, J. Lu, Q-Y. Chen, L-L. Cao, M. Lin, R-H. Tu, Z-N. Huang, J-L. Lin, H-L. Zheng, C. Huang
Journal: Annals of Oncology (2020)
Ulcerative Colitis-associated <i>E. coli</i> pathobionts potentiate colitis in susceptible hosts
Authors: Hyungjun Yang, Hengameh Chloé Mirsepasi-Lauridsen, Carsten Struve, Joannie M. Allaire, Adeline Sivignon, Wayne Vogl, Else S. Bosman, Caixia Ma, Abbas Fotovati, Gregor S. Reid, Xiaoxia Li, Andreas Munk Petersen, Sébastien G. Gouin, Nicolas Barnich, Kevan Jacobson, Hong Bing Yu, Karen Angeliki Krogfelt, Bruce A. Vallance
Journal: Gut Microbes (2020)

Ulcerative colitis (UC) is a chronic inflammatory condition linked to intestinal microbial dysbiosis, including the expansion of E. coli strains related to extra-intestinal pathogenic E. coli. These "pathobionts" exhibit pathogenic properties, but their potential to promote UC is unclear due to the lack of relevant animal models. Here, we established a mouse model using a representative UC pathobiont strain (p19A), and mice lacking single immunoglobulin and toll-interleukin 1 receptor domain (SIGIRR), a deficiency increasing susceptibility to gut infections. Strain p19A was found to adhere to the cecal mucosa of Sigirr -/- mice, causing modest inflammation. Moreover, it dramatically worsened dextran sodium sulfate-induced colitis. This potentiation was attenuated using a p19A strain lacking α-hemolysin genes, or when we targeted pathobiont adherence using a p19A strain lacking the adhesin FimH, or following treatment with FimH antagonists. Thus, UC pathobionts adhere to the intestinal mucosa, and worsen the course of colitis in susceptible hosts.
Altered Biodistribution of 68Ga-DOTATOC
Authors: Anne-Claire Dupont, Fanny Borrelly, Thierry Lecomte, Serge Maia, Maria-Joao Santiago Ribeiro
Journal: Clinical Nuclear Medicine (2020)

Abstract 68 Ga-DOTATOC PET/CT of a patient with metastatic neuroendocrine tumor reveals an abnormal biodistribution of the tracer with a vascular binding and a very low fixation on the known lesions despite the temporary discontinuation of “cold” somatostatin analogs. A possible interaction with a high intake of turmeric may be suspected by inhibition of hepatic uptake process.
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Authors: Thierry André, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fouchardiere, Fernando Rivera, Elena Elez, Johanna Bendell, Dung T. Le, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Z.H. Farooqui, Patricia Marinello, Luis A. Diaz
Journal: New England Journal of Medicine (2020)

Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 blockade as compared with chemotherapy as first-line therapy for MSI-H–dMMR advanced or metastatic colorectal cancer is unknown.
223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Authors: K. Fizazi, N.D. Shore, T.L.J. Tammela, A. Ulys, E. Vjaters, S. Polyakov, M. Jievaltas, M. Luz, B. Alekseev, I. Kuss, M-A. Le Berre, O. Petrenciuc, A. Snapir, T. Sarapohja, M.R. Smith
Journal: Annals of Oncology (2020)
Abstract 13233: Effect of Ultrasound Transducer Frequency on Longitudinal Strain Measurement by 2d Speckle Tracking Echocardiography
Authors: Katsuomi Iwakura, Atsunori Okamura, Yasushi Koyama, Koichi Inoue, Mutsumi Iwamoto, Hiroyuki Nagai, Yuko Hirao, Koji Tanaka, Takafumi Oka, Nobuaki Tanaka, Yuichi Ninomiya, Masato Okada, Akinori Sumiyoshi, Hiroyuki Inoue, Kota Tanaka, Kohtaro Takayasu, Kenshi Fujii
Journal: Circulation (2018)

Background: Two-dimensional speckle-tracking echocardiography (STE) is based on frame-by-frame tracking of echo-dense speckles within the myocardium and subsequent measurement of LV deformation. Ac...
Screening for infantile hepatic hemangioma in patients with cutaneous infantile hemangioma: A multicenter prospective study
Authors: Yi Ji, Siyuan Chen, Kaiying Yang, Bo Xiang, Xian Jiang, Xuewen Xu, Lizhi Li, Tong Qiu, Jiangyuan Zhou, Shiyi Dai, Xuepeng Zhang, Guoyan Lu, Feiteng Kong, Gang Yang, Qingxia Qiu
Journal: Journal of the American Academy of Dermatology (2020)
16194 A GAPO syndrome case report: Identification of novel biallenic ANTXR1 variants cause GAPO syndrome
Authors: Vien The Tran, BaoChi Bui, Anh Quynh Ngoc Phan, An Le Pham, Lien Kim Thi Ha, Minh Van Hoang, Vien The Tran, Phung Kim Thi Ngo
Journal: Journal of the American Academy of Dermatology (2020)
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Authors: Ventura A Simonovich, Leandro D Burgos Pratx, Paula Scibona, María V Beruto, Marcelo G Vallone, Carolina Vázquez, Nadia Savoy, Diego H Giunta, Lucía G Pérez, Marisa Del L Sánchez, Andrea Vanesa Gamarnik, Diego S Ojeda, Diego M Santoro, Pablo J Camino, Sebastian Antelo, Karina Rainero, Gabriela P Vidiella, Erica A Miyazaki, Wanda Cornistein, Omar A Trabadelo, Fernando M Ross, Mariano Spotti, Gabriel Funtowicz, Walter E Scordo, Marcelo H Losso, Inés Ferniot, Pablo E Pardo, Eulalia Rodriguez, Pablo Rucci, Julieta Pasquali, Nora A Fuentes, Mariano Esperatti, Gerardo A Speroni, Esteban C Nannini, Alejandra Matteaccio, Hernán G Michelangelo, Dean Follmann, H Clifford Lane, Waldo H Belloso
Journal: New England Journal of Medicine (2020)

BackgroundConvalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled trials.MethodsWe randomly assigned hospitalized adult patients with severe Covid-19 pneumonia in a 2:1 ratio to receive convalescent plasma or placebo. The primary outcome was the patient's clinical status 30 days after the intervention, as measured on a six-point ordinal scale ranging from total recovery to death.ResultsA total of 228 patients were assigned to receive convalescent plasma and 105 to receive placebo. The median time from the onset of symptoms to enrollment in the trial was 8 days (interquartile range, 5 to 10), and hypoxemia was the most frequent severity criterion for enrollment. The infused convalescent plasma had a median titer of 1:3200 of total SARS-CoV-2 antibodies (interquartile range, 1:800 to 1:3200). No patients were lost to follow-up. At day 30 day, no significant difference was noted between the convalescent plasma group and the placebo group in the distribution of clinical outcomes according to the ordinal scale (odds ratio, 0.83; 95% confidence interval [CI], 0.52 to 1.35; P=0.46). Overall mortality was 10.96% in the convalescent plasma group and 11.43% in the placebo group, for a risk difference of −0.46 percentage points (95% CI, −7.8 to 6.8). Total SARS-CoV-2 antibody titers tended to be higher in the convalescent plasma group at day 2 after the intervention. Adverse events and serious adverse events were similar in the two groups.ConclusionsNo significant differences were observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo. (PlasmAr ClinicalTrials.gov number, NCT04383535.)
SAT0077 CARDIOVASCULAR RISK ASSESSMENT WITH CAROTID ULTRASONOGRAPHY IN ADDITION TO THE TRADITIONAL CARDIOVASCULAR RISK FACTORS IN RHEUMATOID ARTHRITIS PATIENTS: A CASE CONTROL STUDY
Authors: R. Gonzalez Mazario, J. J. Fragio-Gil, P. Martinez Calabuig, E. Grau García, M. De la Rubia Navarro, C. Pávez Perales, S. Leal Rodriguez, I. Martínez Cordellat, J. Ivorra Cortés, R. Negueroles Albuixech, J. E. Oller Rodríguez, L. Gonzalez Puig, C. Alcañiz Escandell, I. Chalmeta Verdejo, F. M. Ortiz Sanjuan, E. Vicens Bernabeu, I. Cánovas Olmos, C. Nájera Herranz, J. A. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2020)

Background: Cardiovascular disease (CV) is the most frequent cause of death in rheumatoid arthritis (RA) patients. It is well known that RA acts as an independent cardiovascular risk factor. Objectives: To assess the CV risk in RA patients using carotid ultrasonography (US) additionally to the traditional CV risk factors. Methods: A prospective transversal case control study was performed, including adult RA patients who fulfilled ACR/EULAR 2010 criteria and healthy controls matched according to CV risk factors. Population over 75 years old, patients with established CV disease and/or chronic kidney failure (from III stage) were excluded. The US evaluator was blinded to the case/control condition and evaluated the presence of plaques and the intima-media thickness. Statistical analysis was performed with R (3.6.1 version) and included a multivariate variance analysis (MANOVA) and a negative binomial regression adjusted by confounding factors (age, sex and CV risk factors). Results: A total of 200 cases and 111 healthy controls were included in the study. Demographical, clinical and US data are exposed in table 1. Not any difference was detected in terms of CV risk factors between the cases and controls. In both groups a relationship between age, BMI and high blood pressure was detected (p&lt;0.001). Table 1. Table 2. RA basal characteristics Disease duration (years) 16,98 (11,38) Erosions (X-Ray of hands/feet) 163 (81,5%) Seropositive (RF/anti-CCP) 146 (73%) Extra-articular symptoms 44 (22%) Intersticial difusse lung disease 10 (5%) Rheumatoid nodules 14 (7%) Prednisone use 103 (51,5%) Median dose of Prednisone last year (mg) 2,34 (2,84) sDMARDs Methotrexate 104 (52%) Leflunomide 29 (14,5%) Hydroxycloroquine 9 (4,5%) bDMARDs 89 (44,5%) TNFi 41 (20,5%) Abatacept 15 (7,5%) IL6i 22 (11%) RTX 11 (5,5%) JAKi 26 (13%) Baricitinib 11 (5,5%) Tofacitinib 15 (7,5%) DAS 28-ESR 3,1 (2,3, 3,9) SDAI 7,85 (4,04, 13,41) HAQ 0,88 (0,22, 1,5) RF (U/mL) 51 (15, 164,25) Anti-CCP (U/mL) 173 (22, 340) Patients showed higher intima-media (both right and left) thickness compared to controls (p&lt;0.006). Moreover it was also related to the disease duration and DAS28 score (p&lt;0.001). A higher plaque account was noted in cases(p&lt;0.004) and it was also related to the disease duration (p&lt;0.001). Conclusion: RA implies a higher CV risk. Traditional CV risk factors explains only partially the global risk. These findings support that RA acts as an independent cardiovascular risk factor. Disclosure of Interests: None declared
CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy
Authors: Fraser Soares, Branson Chen, Jong Bok Lee, Musaddeque Ahmed, Dalam Ly, Enoch Tin, Hyeonjeong Kang, Yong Zeng, Nayeema Akhtar, Mark D. Minden, Housheng Hansen He, Li Zhang
Journal: Blood (2020)